Introduction
============

Colorectal cancer accounts for one third of cancer-related deaths worldwide and this trend is still increasing. Although application of comprehensive treatments, including surgery, has achieved a significant improvement in the 5-year survival rate, the overall estimated death rate is still \~50%--60%.[@b1-ott-9-1159] Early diagnosis is thus an effective way to prolong life of patients with colorectal cancer.

The term micro-RNA (miRNA) refers to a type of small RNA of length 19--22 nucleotides in vivo. After a series of reactions, it finally forms an RNA-induced silencing complex. The miRNA-associated RNA-induced silencing complex binds to its target messenger RNA (mRNA) at the 3′-untranslated region, so that it can cleave and degrade the target mRNA or inhibit further translation of the target mRNA, leading to a loss of function of the target gene.

miRNA plays an important role in the occurrence and development of colorectal cancer. miRNA affects many known oncogenes and antioncogenes and is involved in the regulation of the signal transduction pathway related to colorectal cancer. Thus, miRNAs, many of which have differential expression profiles, may be used to serve as biological markers for predicting the development of and prognosis of colorectal cancer.[@b2-ott-9-1159],[@b3-ott-9-1159]

In recent years, changes of miRNA levels in the human circulation have gained more attention for their role in the early diagnosis of colorectal cancer.[@b3-ott-9-1159]--[@b5-ott-9-1159] Luo et al[@b3-ott-9-1159] used TaqMan miRNA slugs in 50 cases of colorectal cancer and 50 cases of adenoma and found nine miRNAs that had differential expression in colorectal cancer when compared to normal mucosa. They hypothesized that assay of these nine markers can contribute to the early diagnosis of colorectal cancer. Ng et al[@b4-ott-9-1159] assayed 90 known miRNAs in 90 cases of colorectal cancer, 20 cases of gastric cancer, 20 cases of inflammatory bowel disease, and 50 healthy people. Their findings showed that miR-17-3p and miR-92 were increased in patient blood, and further verification showed that, among the 180 cases, miR-92 had a distinct increase in patient blood. In contrast to the report by Ng et al,[@b4-ott-9-1159] Faltejskova et al,[@b6-ott-9-1159] by repeating the research performed by Ng et al[@b4-ott-9-1159] among Czech patients, found that the levels of miR-17-3p (*P*=0.18), miR-29a (*P*=0.14), and miR-92a (*P*=0.60) had no significant difference in colorectal cancer when compared to a control group. The differences in findings might have been due to the distinct sources of samples, including the regional environment distinction of patient samples.

The colorectal cancer screen using miRNAs was claimed to have sensitivity of 89% and specificity of 70%. Research reported by Huang et al[@b5-ott-9-1159] found that using miR-29a and miR-92a as biomarkers for early diagnosis had 83% sensitivity and 84.7% specificity for colorectal cancer diagnosis and 77% sensitivity and 79.7% of specificity for colorectal polyps.

Although previous studies showed valuable data on miRNAs as potential biomarkers in colorectal cancer, results were still limited and were sometimes contradictory with each other due to different sources of samples.[@b3-ott-9-1159]--[@b5-ott-9-1159] Cancer-stage-related miRNAs as valuable biomarkers are still lacking. In this study, controlled experiments were performed on colorectal cancer with its distinct developmental stages, including colorectal polyps, and on normal mucosa. miRNA deep sequencing was performed on cancer and precancer tissues of all stages, to determine simultaneous variations in the miRNA index for colorectal cancer and colorectal polyps. This index can be used in further studies to confirm its value in the early diagnosis of colorectal cancer.

Materials and methods
=====================

Clinical specimens
------------------

The specimens used for the deep sequencing were from four typical patients who had undergone surgery or endoscopy at the National Center of Colorectal Surgery, the Third Affiliated Hospital of Nanjing University of Traditional Chinese Medicine. One case was a 52-year-old female, a patient with colorectal cancer (T2N0M0) who had anterior resection operation; the cancer tissue and normal mucosa were taken for study. Another case was a 50-year-old male with sigmoid cancer with a colon polyp (T3N0M0), who had received a sigmoidectomy operation for sigmoid cancer and endoscopic polypectomy for colon adenoma; the cancer, adenoma, and normal mucosa tissues were taken for study. A third case was a patient with polyps in the cecum and cancer of the horizontal colon (T3N1M0); a right hemicolectomy surgery was performed; his cancer, adenoma, and normal mucosa tissues were obtained for study. A fourth case had a polyp of the sigmoid colon; endoscopic mucosal resection was performed and specimens were taken for study. In total, there were three samples each of cancer, adenoma, and normal mucosa tissues. All samples were preserved in liquid nitrogen. The study was approved by the Ethics Committee of The Third Affiliated Hospital of Nanjing, University of Traditional Chinese Medicine, and all patients provided written informed consent.

miRNA deep sequencing
---------------------

We implemented miRNA deep sequencing with the method published by Schee et al[@b7-ott-9-1159] and carried out high-throughput sequencing on the specimens using the 50 bp single-end sequencing model on an Illumina HiSeq2500 (Illumina, San Diego, CA, USA) sequencing platform. Frozen specimens were used with the Sangong kit (Sangong Biotechnology, Shanghai, People's Republic of China) for total RNA extraction. The total RNA was quantified with NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA), and 500 ng of total RNA was visualized on 1% agarose gel after electrophoresis. A miRNA library was established with the TruSeq^®^ miRNA Sample Prep Kit v2 (Illumina Company), with reverse transcriptase polymerase chain reaction (RT-PCR) to enrich the library and with Qubit kit (Thermo Fisher Scientific) to quantify miRNA libraries. Sequencing was performed with the HiSeq2500. The data were transformed into the FASTQ format for expression and differential profile analysis. The results were subjected to cluster analysis with Illumina's software packages (SCS2.9/RTA1.9 and Off-line Basecaller v1.9). miRNAs that were differentially expressed, either increased or decreased, in colorectal cancer and colorectal adenoma samples were selected for the analysis.

Quantitative RT-PCR test and verification of miRNA deep-sequencing results
--------------------------------------------------------------------------

Twelve colorectal cancer tissues as well as normal mucosa (\>10 cm away from the cancer) and 12 samples of colonic adenoma were used for quantitative RT-PCR (qRT-PCR) validation of the differentially expressed miRNAs revealed by the deep sequencing. The RNA samples were derived from patients with colorectal cancer; seven were males and five were females, with ages ranging from 35 years to 75 years and a median age of 65 years. These included six cases of colorectal cancer, four cases of sigmoid cancer, and two cases of ascending colon cancer. Additional validations were conducted by using RNA samples from 12 patients with colorectal adenomas, eight males and four females with ages ranging from 40 years to 73 years and a median age of 62 years. These included seven cases of rectal polyps, four cases of sigmoid colon polyps, and one case of ascending colon polyps.

We designed reverse transcription stem--loop primer and specificity amplification primers, and the RNU6 qRT-PCR was used as an internal reference for miRNA quantification. The average Ct value of three replicates was calculated for each sample. The Ct values of the internal reference were also obtained three times and used for sample value corrections. The corrected Ct values were directly plotted for differential expression analysis. Please note that the samples were not paired in experiments, and therefore their Ct values were unfit for the calculation of 2^−ΔΔCt^ (cannot appropriately subtract the Ct value of one sample as a control group). Therefore, direct plotting of the Ct value, which was subtracted from the expression of the internal reference of normal, adenoma, and cancer tissues, was used for their expressions. One-way analysis of variance in a normal distribution and the Mann--Whitney *U*-test equivalent, an inspection method for nonnormal distribution or variance, were used to test all groups studied.

Results
=======

Differential expression of miRNAs in different developmental stages of colorectal cancerous tissues
---------------------------------------------------------------------------------------------------

To analyze the differential expression of miRNAs in different stages of colorectal cancerous tissues, miRNAs with two-fold changes were compared for their expression patterns among adenoma, cancer, and normal mucosa (*P*≤0.05, expression quantity with two-fold changes). We conducted the following comparisons ([Figure 1](#f1-ott-9-1159){ref-type="fig"} and [Table 1](#t1-ott-9-1159){ref-type="table"}): 1) between cancerous tissue and normal mucosa tissue; 2) between adenoma and normal mucosa; and 3) between cancer and adenoma. Our data analysis showed that 99 miRNAs were upregulated and 90 miRNAs were downregulated in cancers relative to normal mucosa. Furthermore, 114 miRNAs were found to be upregulated and 107 downregulated in adenoma compared with normal mucosa. Seventy miRNAs were upregulated and 27 down-regulated in cancers relative to adenoma miRNAs. Among all the upregulated miRNAs, 32 miRNAs were simultaneously upregulated in both cancer and adenoma, and nine had significantly differential expression between adenoma and cancer. Among all the downregulated miRNAs, 27 miRNAs were simultaneously decreased in both adenoma and cancer, and only two had significant differential expression between adenoma and cancer. Nine miRNAs, increased or decreased in both colorectal cancer and colorectal adenomas, were chosen for further validation.

Validation of the differentially expressed miRNAs in colorectal cancer tissues of patients
------------------------------------------------------------------------------------------

To verify the reliability of the deep-sequencing data, we picked 12 miRNAs that were found to be differentially expressed by deep sequencing. The validation was conducted using more samples of a Chinese patient population, and the data are shown in [Figures 2](#f2-ott-9-1159){ref-type="fig"} and [3](#f3-ott-9-1159){ref-type="fig"}.

For the upregulated miRNAs ([Figure 2](#f2-ott-9-1159){ref-type="fig"}), miR-18a-5p and miR-21-3p were statistically significantly increased in both adenoma and cancer tissues, compared to the normal mucosa. miR-135b-5p, miR-17-5p, miR-182-5p, miR-200a-5p, and miR-200c-3p were significantly upregulated in cancer compared with the normal mucosa tissues but not significantly in adenoma relative to normal mucosa tissues. miR-183-5p and miR-96-5p were significantly upregulated in adenoma compared with normal mucosa tissues but showed no differential expression between cancer and normal mucosa.

For the downregulated miRNA ([Figure 3](#f3-ott-9-1159){ref-type="fig"}), only miR-133a-3p was significantly downregulated in both adenoma and cancer tissues when compared with normal mucosa. miR-204-5p, miR-125b-5p, miR-139-5p, miR-100-5p, and miR-30a-5p were significantly downregulated in cancer relative to normal mucosa but not significantly in adenoma compared with normal mucosa tissues. Among these down-regulated miRNAs, no miRNA showed any differential expression either between adenoma and cancer tissues or between cancer and normal mucosa tissues. The statistical results are shown in [Table 2](#t2-ott-9-1159){ref-type="table"}.

Discussion
==========

The use of molecular biomarkers for the early diagnosis of colorectal cancer is an important topic of current research.[@b2-ott-9-1159]--[@b4-ott-9-1159] Recent studies have found that miRNA plays an important role in the pathogenesis and development of colorectal cancer.[@b2-ott-9-1159]--[@b4-ott-9-1159] The use of the characteristics of miRNAs, which can be detected at early stages in the blood circulation system, for early diagnosis of cancers has achieved very promising results.[@b4-ott-9-1159]--[@b7-ott-9-1159] However, due to miRNA expression variations among different races, environments, diet styles, and so on, the results of the detected miRNA expressions may be different. In this study, small RNA deep-sequencing experiments were specifically conducted on samples of patients with colorectal cancer from Southeast China for studying the differential expression patterns of miRNAs among samples of different cancer developmental stages. The objective was to determine a standard and valuable miRNA diagnostic index for the early detection of colorectal cancers in patients of Southeast China.

In this study, using deep sequencing, we detected two major types of miRNAs that are differentially expressed in different colorectal samples: 99 upregulated miRNAs and 90 downregulated miRNAs in colorectal cancer, as well as 70 upregulated and 27 downregulated miRNAs in adenoma tissues. The results were largely similar to previous reports[@b2-ott-9-1159]--[@b7-ott-9-1159] and confirmed the reliability of our experiments used for the analysis of distinct samples of Southeast China. Our data were also cross-validated by comparison between the deep-sequencing results and the qRT-PCR validation results. We further identified that miR-18a-5p and miR-21-3p were upregulated in both adenoma and cancer tissues, while miR-133a-3p was downregulated in both adenoma and cancer tissues, which offers potential early miRNA indicators for colorectal cancer screening.

Research reported by Slattery et al[@b8-ott-9-1159] found that overexpression of hsa-miR-18a-5p can reduce the risk of death from colorectal cancer. A systematic review reported by Clancy et al[@b9-ott-9-1159] found that patients with colorectal cancers show upregulation of circulating hsa-miR-18a-5p, which may imply that hsa-miR-18a-5p can be used as a diagnostic marker. Calvano Filho et al[@b10-ott-9-1159] also found that the expression of hsa-miR-18a-5p increases in breast cancer and this suggested a correlation may exist for other types of cancers.

Similarly, upregulation of miR-21-3p was found not only for colorectal cancer but also for a variety of cancers. Rotelli et al[@b11-ott-9-1159] found that miR-21-3p was increased in the stools of patients with colorectal cancer and that it decreased after surgery, which suggests that it can be used as a prognostic factor for colorectal cancer. Other studies have found that miR-21-3p is associated with gynecological tumors and drug resistance.[@b12-ott-9-1159] A few studies investigating whether it increases in colorectal cancer and colorectal adenoma have been conducted.[@b12-ott-9-1159],[@b13-ott-9-1159] Research reported by Doberstein et al[@b14-ott-9-1159] found that miR-21-3p increased with tumorigenesis in a variety of tumors. In contrast, few studies have been conducted on the role of miR-133a-3p in the pathogenesis and development of colorectal cancer.[@b15-ott-9-1159]

In this research, differences in expression of miR-135b-5p, miR-17-5p, miR-182-5p, miR-200a-5p, and miR-200c-3p were statistically significant in comparisons between cancer and normal mucosa tissues, while no significance was observed for adenoma and normal mucosa tissues. The differences in miR-183-5p and miR-96-5p expression were statistically significant for adenoma and normal mucosa tissues and showed no significant differences in cancer and normal mucosa tissues.

In our miRNA deep-sequencing study, the expression patterns of miRNAs were similar in both adenoma and cancer tissues. This result might be due to several reasons. One explanation may be the small number of patients in this study, which requires further investigations either using larger sample numbers for the deep sequencing or more validations using larger patient samples. Our next step will be the verification of its value in more colorectal cancer samples. According to the literature, variations in miRNA detection were also associated with varying sources of patients with cancer. There may exist miRNA expression differences between different human races or humans with different environmental or diet habits. One of our research objectives is to identify such potential distinctions of miRNA expressions in different Chinese patient populations for a more precise medication. This study aimed to determine the links between miRNA biomarker variation and the occurrence of colorectal cancer in patients of Southeast China.[@b16-ott-9-1159]--[@b22-ott-9-1159]

In conclusion, this research found a number of important miRNAs that may have diagnostic and prognostic significance in the occurrence and development of colorectal cancer. miR-18a-5p, miR-21-3p, and miR-133a-3p were found to be up- or downregulated in both adenoma and cancer tissues and can be used as early indicators of colorectal cancer during screening, while the increase or decrease of miR-135b-5p, miR-17-5p, miR-182-5p, miR-200a-5p, miR-200c-3p, miR-183-5p, and miR-96-5p in both cancer and adenoma tissues showed no obvious differences. Further research is necessary for determining the appropriate screen index values that can be used for the diagnosis of colorectal cancer.
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![The results of deep sequencing of colorectal cancer miRNAs.\
**Notes:** Three types of tissues were derived from four different patients (1--4) (**A**). The symbol "+" indicates that samples were collected and "−" indicates that samples were not able to be collected. The distribution of upregulated miRNAs and their overlapping expressions in different tissues are shown in (**B**). The distribution of downregulated miRNAs and their overlapping expressions in different tissues are shown in (**C**).\
**Abbreviation:** miRNA, microRNA.](ott-9-1159Fig1){#f1-ott-9-1159}

![Verification results of upregulated miRNA.\
**Note:** Figure shows the Ct value of every upregulated miRNA and its 95% confidence interval in normal mucosa, adenoma, and cancer tissues.\
**Abbreviations:** miRNA, microRNA; Ct, cycle threshold; RNU6, cycle run six cycle.](ott-9-1159Fig2){#f2-ott-9-1159}

![Verification results of downregulated miRNA.\
**Note:** Figure shows the Ct value of every downregulated miRNA and its 95% confidence interval in normal mucosa, adenoma, and cancer tissues.\
**Abbreviations:** miRNA, microRNA; Ct, cycle threshold; RNU6, cycle run six cycle.](ott-9-1159Fig3){#f3-ott-9-1159}

###### 

miRNA markers were both upregulated and downregulated in both adenoma and cancer tissues

  Upregulated miRNA in both adenoma and cancer   Downregulated miRNA in both adenoma and cancer
  ---------------------------------------------- ------------------------------------------------
  hsa-miR-29b-3p                                 hsa-miR-135a-5p
  hsa-miR-362-5p                                 hsa-miR-9-5p
  hsa-miR-182-5p                                 hsa-miR-129-5p
  chr7_9113                                      hsa-miR-204-5p
  hsa-miR-584-5p                                 chr20_19299
  chrX_21021                                     chr9_10749
  hsa-miR-1268b                                  hsa-miR-3195
  hsa-miR-552-3p                                 hsa-miR-145-5p
  hsa-miR-21-3p                                  hsa-miR-133a-3p
  hsa-miR-96-5p                                  hsa-miR-195-3p
  hsa-miR-17-5p                                  hsa-miR-328-3p
  hsa-miR-20a-5p                                 hsa-miR-30c-2-3p
  chr21_19839                                    hsa-miR-139-5p
  chr7_9117                                      hsa-miR-504-5p
  hsa-miR-3182                                   chr17_17056
  hsa-miR-27a-5p                                 chr19_18516
  hsa-miR-183-5p                                 chr4_5126
  hsa-miR-548d-5p                                chr17_17055
  hsa-miR-18a-5p                                 hsa-miR-30a-5p
  hsa-miR-23a-5p                                 chr5_6947
  chr17_16945                                    chr6_7381
  hsa-miR-135b-5p                                hsa-miR-30a-3p
  hsa-miR-224-5p                                 hsa-miR-1
  chr15_15541                                    hsa-miR-195-5p
  hsa-miR-1246                                   chr12_13116
  chr15_15204                                    
  chr15_15541_star                               
  chr15_15204_star                               
  chr1_1473_star                                 
  chr4_5063                                      
  hsa-miR-548d-3p                                

**Abbreviation:** miRNA, microRNA.

###### 

miRNA verification results

  miRNA           Average value X ± SD   *P*-value                                 
  --------------- ---------------------- ------------ ------------ ------- ------- -------
  Upregulated                                                                      
   miR-135b-5p    17.42±2.41             17.41±1.64   14.68±2.25   0.985   0.009   0.003
   miR-183-5p     21.23±3.69             27.36±2.35   21.48±2.72   0.001   0.85    0.001
   miR-96-5p      18.33±2.72             21.80±2.30   19.33±2.40   0.003   0.352   0.018
   miR-18a-5p     16.59±1.99             18.48±1.68   14.23±1.59   0.02    0.004   0.001
   miR-21-3p      24.99±2.52             17.03±3.96   16.90±5.40   0.001   0.001   0.949
   miR-17-5p      21.25±7.10             17.68±4.14   12.00±2.58   0.119   0.005   0.001
   miR-182-5p     23.51±3.91             25.12±3.16   19.04±2.74   0.28    0.004   0.001
   miR-200a-5p    22.20±6.26             22.90±3.54   13.86±3.40   0.74    0.001   0.001
   miR-200c-3p    23.90±4.74             21.42±3.83   13.63±3.63   0.172   0.001   0.001
  Downregulated                                                                    
   miR-204-5p     12.60±5.15             16.73±3.75   16.35±4.94   0.035   0.083   0.833
   miR-133a-3p    9.16±3.74              14.93±2.26   15.21±3.11   0.001   0.001   0.802
   miR-145-5p     14.10±4.21             16.94±4.71   12.90±7.91   0.134   0.65    0.143
   miR-145-3p     11.55±4.00             14.78±4.74   15.26±7.46   0.085   0.143   0.851
   miR-1          19.53±4.56             19.40±3.19   21.40±4.72   0.934   0.335   0.236
   miR-125b-5p    9.18±3.65              11.26±7.96   16.60±6.04   0.424   0.001   0.083
   miR-139-5p     13.50±3.69             17.30±6.79   21.42±3.64   0.102   0.001   0.078
   miR-100-5p     13.05±3.49             14.00±4.28   20.00±2.69   0.558   0.001   0.001
   miR-30a-5p     11.80±2.82             12.16±4.46   17.65±2.94   0.729   0.001   0.002

**Abbreviation:** miRNA, microRNA.
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